Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2008-04-01
2008-04-01
Kifle, Bruck (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C514S220000
Reexamination Certificate
active
07351701
ABSTRACT:
The invention relates to trycyclic lactam indole derivatives and triacyclic lactam benzimodole derivatives and their use in inhibiting the activity of PARP enzyme. The invention also relates to the use of these compounds in the preparation of medicaments.
REFERENCES:
patent: 6495541 (2002-12-01), Webber et al.
patent: 6548494 (2003-04-01), Webber et al.
patent: 2004/0248879 (2004-12-01), Canan-Koch et al.
patent: 2005/0059663 (2005-03-01), Martin et al.
patent: 2005/0227919 (2005-10-01), Ashworth et al.
patent: 2006/0074073 (2006-04-01), Steinfeldt et al.
patent: 0042040 (2000-07-01), None
patent: 0116136 (2001-03-01), None
patent: 2004087713 (2004-10-01), None
patent: 2005012305 (2005-02-01), None
patent: 2005012524 (2005-02-01), None
Bryant, et al., Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase, Nature, Apr. 14, 2005, 913-917, vol. 434.
Canan Koch, et al., Novel Tricyclic Poly(ADP-ribose) Polymerase-1 Inhibitors with Potent Anticancer Chemopotentiating Activity: Design, Synthesis, and X-ray Cocrystal Structure, J. Med. Chem., 2002, 4961-4974, vol. 45, No. 23.
Easton, et al., Cancer Risks in BRCA2 Mutation Carriers, J. Natl. Cancer Inst., 1999, 1310-1316, vol. 91, No. 15.
Farmer, et al., Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy, Nature, Apr. 14, 2005, 917-921, vol. 434.
Friedenson, et al., BRCA1 and BRCA2 Pathways and the Risk of Cancers Other Than Breast or Ovarian, Medscape General Medicine, 2005, 7(2):60.
Lakhani, et al., The Pathology of Familial Breast Cancer: Predictive Value of Immunohistochemical Markers Estrogen Receptor, Progesterone Receptor, HER-2, and p53 in Patients With Mutations in BRCA1 and BRCA2, Journal of Clinical Oncology, May 1, 2002, 2310-2318, vol. 20, No. 9.
Quinn, et al., BRCA1 Functions as a Different Modulator of Chemotherapy-induced Apoptosis, Cancer Research, Oct. 1, 2003, 6221-6228, vol. 63.
Taron, et al., BRCA1 mRNA expression levels as an indicator of chemoresistance in lung cancer, Human Molecular Genetics, 2004, 2443-2449, vol. 13, No. 20.
Tutt, et al., The relationship between the roles of BRCA genes in DNA repair and cancer predisposition, Trends in Molecular Medicine, Dec. 2002, 571-576, vol. 8, No. 12.
Venkitaraman, A. R., Cancer Susceptibility and the Functions of BRCA1 and BRCA2, Cell, Jan. 25, 2002, 171-182, vol. 108.
PCT International Search Report for PCT/GB2004/003183 (WO 2005/012305).
PCT Written Opinion of the International Searching Authority for PCT/GB2004/003183 (WO 2005/012305).
Curtin Nicola
Helleday Thomas
Cancer Research Technology Limited
Kifle Bruck
Notaro & Michalos P.C.
Pfizer Inc.
LandOfFree
Therapeutic compounds does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Therapeutic compounds, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Therapeutic compounds will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2776858